Rhumbline Advisers Acquires 9,359 Shares of Sana Biotechnology, Inc. $SANA

Rhumbline Advisers lifted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 5.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,134 shares of the company’s stock after purchasing an additional 9,359 shares during the quarter. Rhumbline Advisers’ holdings in Sana Biotechnology were worth $306,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. SCS Capital Management LLC acquired a new stake in Sana Biotechnology during the 1st quarter worth approximately $137,000. Woodline Partners LP raised its holdings in shares of Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after acquiring an additional 90,515 shares during the period. Clearline Capital LP bought a new stake in Sana Biotechnology in the 1st quarter valued at $690,000. AQR Capital Management LLC boosted its stake in Sana Biotechnology by 49.8% in the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock worth $963,000 after purchasing an additional 190,483 shares during the period. Finally, Vident Advisory LLC increased its holdings in Sana Biotechnology by 37.7% during the 1st quarter. Vident Advisory LLC now owns 59,617 shares of the company’s stock worth $100,000 after purchasing an additional 16,326 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wedbush began coverage on Sana Biotechnology in a research report on Wednesday. They set an “outperform” rating and a $5.00 price objective for the company. Morgan Stanley began coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Sana Biotechnology in a report on Tuesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.50.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA opened at $3.39 on Friday. The stock has a 50 day moving average price of $3.57 and a 200 day moving average price of $2.75. The stock has a market capitalization of $806.18 million, a PE ratio of -3.20 and a beta of 1.88. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.